Companion Diagnostics: Technologies and Markets

  • ID: 4556080
  • Report
  • 352 pages
  • BCC Research
15 % OFF
until Jun 30th 2018
1 of 5

FEATURED COMPANIES

  • Abbott Diagnostics Inc.
  • Astute Medical Inc.
  • Cancer Genetics Inc.
  • Gentronix Ltd.
  • Kiyatec Inc.
  • Precision For Medicine
  • MORE
Report Scope:

The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.

Report Includes:
  • An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
  • Analyses of market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
  • Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
  • Profiles of major players as well as a list of current companies that have new companion diagnostics products in development.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Diagnostics Inc.
  • Astute Medical Inc.
  • Cancer Genetics Inc.
  • Gentronix Ltd.
  • Kiyatec Inc.
  • Precision For Medicine
  • MORE
Chapter 1 Introduction
Study Goals and Objectives
Reasons For Doing the Study
Scope of Report
Intended Audience
Information Sources
Analyst's Credentials
Related Reports
Research Website
Disclaimer

Chapter 2 Summary

Chapter 3 Personalized Medicine Overview

Chapter 4 Cdx Applications Other Than Cancer

Chapter 5 Fda Designated Cdx-Cancer

Chapter 6 Current Techniques, Technologies and Market Structures

Chapter 7 Not Fda Required

Chapter 8 Emerging Liquid Biopsy Market

Chapter 9 Universal Cdx

Chapter 10 Future Applications: Cardiovascular and Metabolic Disease

Chapter 11 Representative Acquisitions and Company Profiles
Overview
Oncology As Major Driver
Companion Diagnostics Overview
General Application Categories
Fda Definition
Fda Cleared (510K) and Approved (Pma) Market
Beyond Fda Designated Cdx
Pharmaceutical-Diagnostic Deals
Company Types
History of Companion Diagnostics
Regulatory Aspects
Key Companies
Cancer Market Segment
Technologies Overview
Reimbursement
Drivers of Adoption
Barriers To Adoption
Cost of Cdx Development
Cdx Regulatory Issues
2015 Precision Medicine Initiative
Potential For Personalized Medicine
Biomarkers
Complementary Dx
Fda Full Cdx Designation
Ldts
Current Market Participants In the Companion Diagnostics Field Are Comprised of Four Major Groups.
In Vitro Diagnostics Companies
Molecular Diagnostics Industry
Companion Diagnostics Companies
Laboratory Test Services Companies
Biomarker Research Companies
Medical Centers
Fda Route
Laboratory-Developed Tests Route
Choosing a Regulatory Pathway
Obstacles
Personalized Medicine Tests
Ivd Diagnostics Industry
Scope
Established Clinical Applications
Current Successes In Pharmacogenomics
Challenges and Future Directions
Validation
Infectious Disease Cdx
Hiv Statistics and Healthcare Cost
Hiv Drug Market
Representative Drug Companies
Viiv
Tropism For Hiv Assay
Competitors of Trofile Assay
Hypersensitivity Test Hla-B 5701
Applications In Vaccine Development
Partnerships and Collaborations For Companion Diagnostics For Infectious Diseases
Other Applications Beyond Hiv
Market Forecast
Overview
Background On Clinical Genomics
Early Focus On Rare Diseases
Challenge of Rare Disease Clinical Trials
Cystic Fibrosis Experience
Driver For Laboratory Developed Tests
Newborn Screening Panel
Data Aggregation and Management
Patient Bias Vs Asymptomatic Screening
Cystic Fibrosis
Ctfr Diagnostics
Next-Generation Sequencing Leadership
Pharmacogenomics
Pharmacogenomics Adoption
Warfarin
Simvastatin
Cancer Drugs
Liver Enzyme Cyp2C19 and Cyp2D6
Clopidigrel
Codeine
Human Leukocyte Antigen B
Carbamazepine
Azathioprine
Mental Health
Antidepressants
Serotonin
Catechol Methyl Transferase
Pharmacokinetic and Pharmacodynamic Genes
Hiv Drug-Resistance Tests
Hepatitis C- Genetic Test For Il28B
Key Learnings
Diagnosis
Tests For Cystic Fibrosis
Targeted Drugs For Cystic Fibrosis
Cisplatin Chemotherapy
Anthracyclines
G6Pd Deficiency
Example: Abacavir
Commercial Example
Example: Elitek and Tumor Lysis Syndrome
Overview
Overview of Cancer
Breast Cancer
Herceptin (Trastuzumab): Roche (Genentech)
Kadcyla: Roche (Genentech)
Perjeta: Roche (Genentech)
Cdx For Herceptin
Manufacturers of Her2 Assays
Epidermal Growth Factor Receptor
Erbitux For Non-Small-Cell Lung Cancer
Tarceva (Erlotinib): Roche/Astellas
Iressa (Gefitinib): Astrazeneca
Gilotrif (Afatinib): Boehringer Ingelheim
T790M Mutation Resistance
Tagrisso (Osimertinib Or Azd9291, Astrazeneca)
Cobas Egfr Mutation Test V2: Roche
Other Drugs For Lung Cancer
Cdx: Therascreen (Pcr)
Colorectal Cancer
Excluding Kras Mutations
Egfr Cdx: Leaders and Followers
Kras Market
Kras Leaders
Anaplastic Lymphoma Receptor Tyrosine Kinase
Ros-1
Ibrance
Braf
Bcr-Abl For Chronic Myelogenous Leukemia
Brca1/2
Cdx: Bracanalysis (Myriad Genetics)
Immune Checkpoint Inhibitors: Keytruda and Opdivo
Pd-1 and Pd-L1 Inhibitors: Protein Markers
Market Forecast
Background: Docetaxel Chemotherapy
Overview
Her2-Positive Breast Cancer
Herceptest (Dako Now Part of Agilent)
Dako Corp - Ihc Antibody
Fish, Ex Pathvysion (Abbott Laboratories)
Life Technologies (Thermo Fisher)
Others
Other Her2 Drugs: Tykerb (Lapatinib), Novartis
Her2 For Other Cancers
Unmet Needs
Non-Small-Cell Lung Cancer
Background: Avastin: Roche (Genentech)
Cdx: Ihc and Fish
Vectibix (Panitumumab): Amgen
Cdx: Egfr Pharmdx Kit (Dako)
Erbitux (Cetuximab): Eli Lilly (Imclone)
Head and Neck Cancers
Differences In the U.S. and Eu
Xalkori (Crizotinib), Pfizer’S Approved Nsclc Therapy
Cdx: Abbott Vysis Fish For Xalkori
Cdx: Ventana
Zelboraf (Vemurafenib) Melanoma: Genentech (Roche)
Cobas 4800 Braf V600 Mutation Test
Mekinist (Trametinib) In Combination With Tafinlar (Dabrafenib): Novartis
Thxid-Braf Kit (Biomérieux Inc.)
Ventana Braf V600 (Ve1) Antibody
Braf Future Research
Overview
Chronic Myelogenous Leukemia
Bcr-Abl
Gleevec
Tests For Gleevec Treatment
Gastrointestinal Stromal Tumor
Cdx: Dako Cytomation's C-Kit (9.7) Pharmdx S2
Asm and Mds/Mpd S2
Cdx: Ldts by Arup Laboratories
Overview
Cdx: Pd-L1 Ihc 22C3 Pharmdx (Dako)
Overview
Foundation: Tissue Dx- Histopathology
Major Types of Tissue Diagnostics
In Practice Used Together
Tissue Dx Market
Cell Dx: Immunohistochemistry, In Situ Hybridization, Dna, and Quantitative Polymerase Chain Reaction
Immunohistochemistry (Ihc)
Fluorescent In Situ Hybridization
Polymerase Chain Reaction
Pros and Cons
Gene Sequencing
Trends
Recap
Ngs As a Growth Driver
Ngs Poised To Dominate
Primer On Ngs Platforms
Ldts: Key Market Structure
Regulatory Drivers
Market Response
Market Forecast
Hematoxylin & Eosin (H&E)
Immunohistochemistry (Ihc)
In Situ Hybridization (Ish)
Example: Ventana (Roche)
Driver: Ffpe Compatibility
Digital Pathology and Quantitative Immunostaining
Future Digital Transformation
Imaging
Protein-Based
Chromosome-Based
Dna-Based
Mrna-Based
Microrna-Based
Metabolite-Based
Imaging-Based
Example: Dako (Now Part of Agilent)
Practical Application
Tissue Context Is Key
Challenges: Quantification
Newer Ihc: Quantitative Immunofluorescence (Qif)
Future Perspectives
Example: Abbott Molecular Diagnostics
Fish Vs Ihc
Chromogenic In Situ Hybridization
Discussion
Overview
Functional Genomics
Somatic Vs Germline Sequencing
Tools Used In Functional Genomics
History of Dna Sequencing
Overview of Dna Sequencing
Rna Sequencing
Increasing Share
Hereditary Cancer Market Leader
Current Tests Mostly Single-Target
Future: More Multi-Gene Panels
Novel Panels Drive Growth and Complexity
Most Common Genes Included In Myriad of Products
Other Sequencing Approaches
Other Technologies
Envisioning Ngs Panels
Enabling New Paradigm: Dx Drives Rx
Fda-Cleared Miseqdx
Clinical Challenges For Ngs
Standardization Challenges For Ngs
Background
Ldt Share of Cdx
Ngs Driving Ldts
Stricter Regulation of Ldts
Implications
Ngs Driving Liquid Biopsy Technology
Example: Nanostring
Example: Dako (Agilent)
Microarrays
Next-Gen Rna Sequencing
Example: Qiagen
Mirna
Proteomics
Metabolomics
Use In Multiplex Assays
Example: Mrna
Proteomics Platforms
Overview
Laboratory-Developed Tests
Breast Cancer Industry
Disease Overview
Ductal Carcinoma In Situ Recurrence
Hormone Sensitivity
Prevention
Overdiagnosis
Treatment
Traditional Drugs
Targeted Therapies For Breast Cancer
Cdx For Herceptin
Emerging Therapies
Diagnosis and Trends
Screening
Biopsy
Laboratory Examination
Market Drivers
Current Commercial Status
Technologies
Cancer Prediction
Early Detection/Screening Tests
Risk Assessment Tests
Lab-Developed Tests: Outlook
Market Forecast
Fda-Approved Kits Or Tests: 510(K) and Pma
Ldt Share of Cdx
Ldt Advantages
Innovation: Panels
Ldt Industry Structure
Regulatory Outlook and Impact
Next Gen Industry Leadership
Key Context of Breast Cancer
Overview of Breast Cancer
Breast Cancer Tests
Drug Pipeline
King of Prognostic and Predictive
Tests To Guide Treatment
Next-Gen Dx Drivers
Classification of Breast Cancer
Breast Cancer Evaluation
Stage of Disease
Oncotype Dx Breast Cancer Test
Estrogen Receptor
Her2 Type
Triple Negative
Causes, Incidence and Risk Factors
Pathophysiology
Er Positive
Metastatic Breast Cancer
Overview
Cancer Treatment: Local Or Systemic
Driven by Stage
Treatment Guidelines
Prognosis After Treatment
Hormone Therapy
Aromatase Inhibitors
Overview
Chemotherapy
Drugs To Control Side Effects of Breast Cancer Treatment
Platinum-Based Chemotherapy
Adjuvant and Neo-Adjuvant Therapy
List of Fda-Approved Drugs
Herceptin (Trastuzumab)
Avastin
Kadcyla: Roche (Genentech)
Perjeta: Roche (Genentech)
Tykerb (Lapatinib): Novartis
Her2 For Other Cancers
Unmet Needs
Triple Negative Breast Cancer
Parp Inhibitors
Brca Targeted Olaparib
Unmet Need: Early Detection and Diagnosis
Early Imaging Tests
Mammography
Magnetic Resonance Imaging of the Breast
Fine Needle Aspiration Biopsy
Core Needle Biopsy
Vacuum-Assisted Biopsies
Surgical (Open) Biopsy
Tissue Diagnostics
Response To Chemotherapy
Genomics Revolution
Dna Repair Pathways
Treatment Selection
Autoimmune Progression (Future)
Overview
Immunohistochemical
Fluorescent In Situ Hybridization
Genomic
Leading Breast Cancer Genomic Tests
Other Genomic Tests
Others
Mostly Ldts
Example: Brca (Myriad)
Discussion
Background
Stricter Regulation of Lab-Developed Tests
Market Response
Implications
Reimbursement
Tamoxifen
Medications For Risk Reduction
Potential Harms of Medications For Risk Reduction
Current Guidelines
Her2 Status Testing
Herceptin For Her2-Low Breast Cancer
Herceptin As Adjuvant
Digital Mammograms
Usefulness of Mammography
Breast Ultrasound
Ductal Lavage and Nipple Aspiration
Three Major Types of Tissue Diagnostics
In Practice Used Together
Market Dynamics
Chemotherapy Response Market
Oncotype Dx For Colon Cancer
Myriad's Colaris
Hereditary Cancer Market
Brca1/2
Myriad's Strategy
Platinum-Based Chemo
Parp Inhibitors
New Myriad Cdx Hrd 2015
Tesaro Hrd
Breast Cancer: Decisions On Adjuvant Chemotherapy
Example: Vectra Da
Example: Mammostrat
Chromogenic In Situ Hybridization
Microarrays
Rt-Pcr
Platform Comparison
Genomic Adoption Pre-Ngs
Next-Generation Sequencing
Implications: More Multi-Gene Panels
Oncotype Dx Assay
Mammaprint by Agendia
Mammostrat
Comparison
Nanostring
Arup
Ihc4 Test
Ipsogen
Example: Ventana (Roche)
Driver: Ffpe Compatibility
Example: Nanostring
Future Digital Transformation
Examples: Genomic Health and Myriad Genomics
Extension: Colon Cancer
Extension: Lung Cancer
Bracanalysis Cdx
Hereditary Next Gen: Myrisk Panel
Extension: Prostate Surveillance
Extension: Melanoma Indeterminate Diagnosis
Examples: Rotterdam Vs Amsterdam
Example: Hereditary Cancer Testing
Current Tests Mostly Single-Target
Prostate Oncotype
Prostate Rna Expression Test
Overview
Phases of Adoption
Limitations of Current Disease Diagnosis
Exosomes: Experiment July 2015
Noninvasive Prenatal Testing As Guide For Liquid Biopsy
Market Forecast
Limitations of Minimally Invasive Methods
Unmet Need: Lung Cancer
Example: Roche Diagnostics
Example: Genestrat and Veristrat by Biodesix
Unmet Need: Bladder Cancer
Example: Oncocyte Technology
Unmet Need: Thyroid Cancer
Screening Opportunities
Example: Lung Cancer Complement To Ct Scanning
Example: Oncocyte
Huge Increase In Screening Opportunity
Technology Overview
Earlier Approaches
Other Companies
Later Approaches
Whole Cell Approach
Cell-Free Dna and Circulating Tumor Dna
Additional Applications
Kras Pancreatic: Small But Clearly Defined
Nssclc: Secondary Egfr Mutation
Kras and Response To Anti-Egfr Drugs
Pd-L1 In Immuno-Oncology
Example: Biocept
Exosomes
Pancreatic Cancer
Market Drivers
Shortcomings
Unmet: Early Detection
Overview
From Noninvasive Prenatal Testing To Maternal Cancers
Noninvasive Prenatal Testing Accelerates Cell-Free Dna
Reimbursement
Strength of Noninvasive Prenatal Testing Companies
Recent Venture Funding
Noninvasive Prenatal Testing Tests and Leading Companies
Patent Pooling
High Risk Only, So Far
Noninvasive Prenatal Testing Market Outlook
Noninvasive Prenatal Testing Plans For Liquid Biopsy
Status of Liquid Biopsy Market
Regulatory Backdrop
Technical Issues
Future Outlook
Lung Tissue Biopsy
Limitations of Urine Cytology
Limitations of Cystoscopy
Example: Veracyte
Background
Ldct Scans For Smokers
Example: Percepta by Veracyte
Follow-On Complementary Need: Pulmonology Idiopathic Pulmonary Fibrosis
Circulating Tumor Cells
Example: Cellsearch (Janssen Diagnostics, Llc)
Apocell
Ichip From Mgh
Challenges In Circulating Tumor Dna Analysis
Example: Boreal Genomics
Example: Guardant Health
Largest Study To Date
Breast Cancer Diagnostic Tests
Urine-Based Tests
Braf Mutation Assay
Egfr Mutation Assays
Example: Exosome Diagnostics
Example: Exosome Diagnostics
Example: Illumina Launching Grail
Sequenom
Ariosa Now Roche
Verinata - Illumina
Natera
Example: Roche
Example: Foundation Medicine
Plan To Submit First Cdx With Clovis
Foundation Sues Guardant
Example: Pathway Genomics Reprimanded
Illumina Grail Strategy
Circulating Tumor Cells
Cell-Free Dna
Sensitivity
Accuracy
Multiplexing
Overview
Indeterminate Mammogram Problem
Confirmatory Application
Screening For Mri Recommended
Huge Screening Opportunity
Overview
Trovagene
Proprietary Sample Preparation
Business Strategy
Focus On Braf and Kras
Melanoma Monitoring Opportunity
Kras Mutations
Colorectal Monitoring
Overview
Drivers
Unmet Need For Whole Genome Sequencing
Market Forecast
Rapid Increase In Targeted Therapies
Limited and Poor Tissue Quality
Physician Difficulty With Complexity
Off-Label Prescription
Difficulty Integrating Into Clinical Practice
Increasing Focus On Community Practices
Regulatory Challenges
Technology Disruption
Economic Disincentives
Biomarker Challenges
Progress From Proteomics
Metabolomics Advantage
Increasing Molecular and Genomics Driven
Existing Single Marker and Gene Panel Approaches
Example: Nanthealth-Gps Cancer
Challenges To Adoption of Comprehensive Molecular Analysis
Examples and Initial Adoption
Foundation Medicine's One Cdx Platform
Nanthealth: Universal Cdx Platform
Target Market
Community-Based Focus
Early Adopters
Future Expansion
Future Market
Precision Medicine Exchange Consortium
Advocate Organizations
Progress and Reimbursement Challenges
Strategic Opptys Via Biopharm Services
Foundationcore Insights
Molecular Profiling
Cdx Services
Progress Update
Decision Support Systems
Competitive Positioning
Potential Market
Cancer Moonshot 2020 Network
Example: Lung-Map Trial
Overview
Applications
Planned Myocardial Ischemia and Infarction
Exercise Stress Testing
Alcohol Septal Ablation
Nitric Oxide Metabolic Pathway
Anthracycline-Induced Cardiotoxicity
Atrial Fibrillation
Pulmonary Arterial Hypertension
Pulmonary Hypertension As Mitochondria Dysfunction
Pulmonary Hypertension and Insulin Resistance
Atherosclerosis Risk
Lipid Profiles
Cholesterol
Particles
Cholesterol Testing Clinical Uses
Statins
Possible Adverse Drug Reactions
Serum Markers
Statin Dose Marker
Coadministration
Metabolization Differences
Genetic Variability
Lipid Profile
Beyond Statins To Multimarker Approach
Jupiter Expands Statin Use
Jupiter Also Raises Diabetes Risk
Guidelines
Systemic and Vascular Inflammation
High-Sensitivity C-Reactive Protein
Myeloperoxidase
Lipoprotein-Associated Phospholipase-A2
Advanced Lipid Testing
Apolipoprotein B and A1 (Apoa1)
Small-Dense Ldl
Lipoprotein (A)
Hdl2B
Particle Type
Companies Offering Advanced Lipid Testing
Liposcale Test
Primary Care Physicians
Cleveland Heartlab
Non-Fasting Triglycerides
Metabolomic Applications
Lipidomics
Choline Metabolism
Acylcarnitines
Trimethylamine N-Oxide
Microflora-Derived Choline Metabolites
Link With Gut Microflora
Diabetes and Pre-Diabetes
Insulin Resistance
Link With Obesity Not Conclusive
Tools To Detect Insulin Resistance
Companies Offering Insulin-Resistance Testing
Other Insulin-Resistance Testing
Liver Diseases
Methylation Deficiency
Folate Deficiency
Clinical Liver Disease
Drug-Induced Liver Injury
Liver Inflammation Models
Commercial Considerations
Market
Jupiter Trial
Branched-Chain Amino Acids: Insulin Resistance Via Exercise Stress Testing
Branched-Chain Amino Acids and Gastric Bypass
Diagnosis
Treatment
Research
Progress On Non-Alcoholic Fatty Liver Disease
One Way Liver Genomics
European Association For the Study of the Liver
Applications In Liver Research
Liver Metabolism Overview
Liver Function and Structure
Example: Kiyatec
Example: Hepregen
Liver Regeneration
Laboratory-Developed Tests
Hepatocytes Or Parenchymal Cells
Specialized Liver Endothelial Cells
Non-Parenchymal Stellate and Kupffer Cells
Morphogen Signaling
In Vitro Applications
Example: Cleveland Heartlab
Abbott Diagnostics Inc.
Advanced Cell Diagnostics Inc.
Agendia Inc.
Almac Group
Altheadx
Ameritox
Amgen Inc.
Applied Biocode
Apocell Inc.
Arrayit Corp.
Arup Laboratories
Assurex Health
Astute Medical Inc.
Asuragen Inc.
Autogenomics Inc.
Beckman Coulter Inc.
Biocartis Nv
Biocept Inc.
Biodesix
Biomerieux
Bio-Rad Inc.
Biotheranostics Inc.
Boreal Genomics
Cancer Genetics Inc.
Cyprotex Plc
Dnavision
Enzo Life Sciences Inc.
Epic Sciences
Epithelix Sarl
Exact Sciences Corp.
Flagship Biosciences Inc.
Genedata
Genelex Corp.
Genomic Health
Gentronix Ltd.
Guardant Health Inc.
Horizon Discovery Ltd.
Htg Molecular Diagnostics Inc.
Illumina Inc.
Imstar S.A.
Inivata Inc.
In Vitro Technologies
Intellicyt Corp.
Intertek
Iris Biotechnologies
Johnson & Johnson Inc.
Kiyatec Inc.
Labcorp
Mdxhealth
Myriad Genetics Inc.
Natera Inc.
Neogenomics Laboratories
Neuroproof Gmbh
Novartis International Ag
Pamgene International B.V.
Panacea Global Inc.
Pathway Genomics Inc.
Pfizer Inc.
Precision For Medicine
Qiagen N.V.
Quest Diagnostics
Randox Biosciences
Roche Diagnostics
Sequenom Inc.
Siemens Medical Solutions USA Inc.
Stemina Biomarker Discovery Inc.
Synvivo Inc.
Sysmex Corp.
Theranostics Health Inc.
Thermo Fisher Scientific Inc.
Trovagene Inc.
Ventana Medical Systems Inc.
Viiv Healthcare
Grades of Breast Cancer

List of Tables
Summary Table: Global Companion Diagnostics Market by Category, Through 2021
Table 1: Novel New Drug Approvals, 2011-2015
Table 2: Novel New Drugs and Percentage Personalized
Table 3: 2015 Newly Approved Medicines
Table 4: Potential Markets For Personalized Medicine
Table 5: Examples of Personalized Medicine Tests
Table 6: Biomarker Applications
Table 7: Biomarkers Used In Companion Diagnostics
Table 8: Fda Designated Cdx
Table 9: Partial List of Fda Cleared and Approved Tests For Cdx Applications
Table 10: Partial List of Biomarkers For Fda Cleared and Approved Cdx Tests
Table 11: Cancer Biomarkers Implemented As Fda Cdx Vs Fda Cleared/Approved Vs Ldts
Table 12: Total Tests Cleared Or Approved by Fda Since 2003
Table 13: Market Shares of Major In Vitro Diagnostics Companies
Table 14: Molecular Diagnostics Companies and Representative Revenue, 2013
Table 15: Market Share of Mdx Sectors
Table 16: Representative List of Cdx Companies
Table 17: Pricing For Common Cancer Drugs
Table 18: Nine Factors That Influence Companion Diagnostic Development and Adoption
Table 19: Established and Emerging Cdx Applications
Table 20: Tests For Cystic Fibrosis
Table 21: G6Pd Testing Companies
Table 22: Cyp Sensitive Drugs
Table 23: Global Human Immunodeficiency Virus Drug Market, 2013 and 2018
Table 24: Companion Diagnostic Tests On the Market For Infectious Diseases, 2013
Table 25: Partnerships In the Field of Companion Diagnostics For Infectious Diseases Between Diagnostics and Pharmaceutical Companies, 2009-2012
Table 26: Global Market For Fda Cleared/Approved Applications Other Than Cancer by Category, Through 2021
Table 27: Fda Designated Cdx by Rx
Table 28: Her2 Cdx Tests Fda Required For Herceptin
Table 29: Fda Required Egfr Cdx Tests
Table 30: Fda Required Kras Cdx Tests
Table 31: Fda Required Alk Cdx Tests
Table 32: Fda Required Braf Cdx Tests
Table 33: Fda Required Cdx Tests For Gleevec
Table 34: Fda Required Brac1/2 Cdx Tests
Table 35: Global Market For Fda Cleared/Approved Cancer Applications by Category, Through 2021
Table 36: Advantages and Disadvantages of the Most Common Techniques For Companion Diagnostics, 2013
Table 37: Global Market For Fda Cleared/Approved Cancer Applications by Category, Through 2021
Table 38: Breast Cancer Stages and Specific Diagnosis
Table 39: Seer Summary Stage System For Breast Cancer
Table 40: Breast Cancer Stages
Table 41: Hormone Therapy Types For Breast Cancer
Table 42: Hormone Therapy Drugs For Breast Cancer
Table 43: Aromatase Inhibitors For Treating Breast Cancer
Table 44: Chemotherapy Drugs For Treating Breast Cancer
Table 45: Drugs Approved To Treat Breast Cancer
Table 46: Targeted Therapeutics For Breast Cancer
Table 47: Her2 Cdx Tests Fda Required For Herceptin
Table 48: Recurrence Rates At Five Years In Patients With Lymph Nodes That Are Positive For Cancer
Table 49: Five-Year Survival Rates Correlated With Tumor Stage
Table 50: Imaging Tests That Determine If Breast Cancer Has Spread
Table 51: Grades of Breast Cancer
Table 52: Myriad Genetics/Cdx Partnerships
Table 53: Ihc and Fish Her2 Tests
Table 54: Genetic Tests For Breast Cancer Treatment
Table 55: Leading Breast Cancer Genomic Tests
Table 56: Gene Expression Profiling Tests
Table 57: Laboratories Offering Brca Tests
Table 58: Next-Generation Breast Cancer Tests
Table 59: Laboratory-Developed Test Providers
Table 60: Global Market For Ldt Cancer Applications by Category, Through 2021
Table 61: Advantages of Liquid Biopsy
Table 62: Ctc Phenotype Criteria Used by Cellsearch
Table 63: Noninvasive Prenatal Testing Adoption Cycle
Table 64: Genetic Testing Companies Market Shares
Table 65: Recent Venture Funding of Liquid Biopsy Companies
Table 66: Global Market For Liquid Biopsy Technology, Through 2021
Table 67: Universal Cdx Companies
Table 68: Global Market For Decision Support Tools From Universal Cdx Developers by Category, Through 2021
Table 69: Global Metabolomics Market by Biomarker, Through 2020
Table 70: Representative Acquisitions

List of Figures
Summary Figure: Global Companion Diagnostics Market by Category, 2015-2021
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Diagnostics Inc.
  • Advanced Cell Diagnostics Inc.
  • Agendia Inc.
  • Almac Group
  • Altheadx
  • Ameritox
  • Amgen Inc.
  • Apocell Inc.
  • Applied Biocode
  • Arrayit Corp.
  • Arup Laboratories
  • Assurex Health
  • Astute Medical Inc.
  • Asuragen Inc.
  • Autogenomics Inc.
  • Beckman Coulter Inc.
  • Bio-Rad Inc.
  • Biocartis Nv
  • Biocept Inc.
  • Biodesix
  • Biomerieux
  • Biotheranostics Inc.
  • Boreal Genomics
  • Cancer Genetics Inc.
  • Cyprotex Plc
  • Dnavision
  • Enzo Life Sciences Inc.
  • Epic Sciences
  • Epithelix Sarl
  • Exact Sciences Corp.
  • Flagship Biosciences Inc.
  • Genedata
  • Genelex Corp.
  • Genomic Health
  • Gentronix Ltd.
  • Guardant Health Inc.
  • Horizon Discovery Ltd.
  • Htg Molecular Diagnostics Inc.
  • Illumina Inc.
  • Imstar S.A.
  • In Vitro Technologies
  • Inivata Inc.
  • Intellicyt Corp.
  • Intertek
  • Iris Biotechnologies
  • Johnson & Johnson Inc.
  • Kiyatec Inc.
  • Labcorp
  • Mdxhealth
  • Myriad Genetics Inc.
  • Natera Inc.
  • Neogenomics Laboratories
  • Neuroproof Gmbh
  • Novartis International AG
  • Pamgene International B.V.
  • Panacea Global Inc.
  • Pathway Genomics Inc.
  • Pfizer Inc.
  • Precision For Medicine
  • Qiagen N.V.
  • Quest Diagnostics
  • Randox Biosciences
  • Roche Diagnostics
  • Sequenom Inc.
  • Siemens Medical Solutions USA Inc.
  • Stemina Biomarker Discovery Inc.
  • Synvivo Inc.
  • Sysmex Corp.
  • Theranostics Health Inc.
  • Thermo Fisher Scientific Inc.
  • Trovagene Inc.
  • Ventana Medical Systems Inc.
  • Viiv Healthcare
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll